Logo

MSD Signs a Clinical Trial Collaboration with Ascentage Pharma for Solid Tumors

Share this

MSD Signs a Clinical Trial Collaboration with Ascentage Pharma for Solid Tumors

Shots:

  • Ascentage will be responsible to sponsor the P-Ib/II trial (NCT03611868) which involves assessing of APG-115 in combination with Keytruda- to evaluate its safety and efficacy in solid tumors (i-e.- NSCLC- melanoma- Urothelial cancer- Liposarcoma- MPNST and ATM mutated/p53 WT tumors resistant or relapsed to PD-1/PD-L1 treatment or without previous PD-1/PD-L1 treatment)
  • The companies will exchange information about the study with the access of the joint development committee. The P-II trial is being initiated and expected to enroll 80 patients in multiple sites across the US
  •  APG-115 is a small-molecule inhibitor of the MDM2-p53 PPI administered orally and has been commenced in three trials in the US and is also the first MDM2-p53 inhibitor to enter in clinical studies in China. Additionally- the P-Ib trial data is being published in ASCO 2020 showing well-tolerated and with anti-tumor effects in several tumor types

Click here to read full press release/ article | Ref: PRNewswire | Image: Twitter


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions